Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema
October 28, 2025 16:05 ET | Source: Tactile Systems Technology, Inc. MINNEAPOLIS,…
DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line
CHONGQING, China, Oct. 22, 2025 /PRNewswire/ -- On October 22, 2025, at…
IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab…
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 19, 2025 08:00 ET | Source: Replimune, Inc. WOBURN, Mass., Oct.…
Sandstone Easydrip Plus Pen Needles Debut in Turkey — PatentProtected Hexagonal Hub for Comfort and Control
Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip;…
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance…
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification, Strengthening Global Leadership in Sustainable and Traceable Supply Chains
KOLKATA, India, Aug. 29, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd (HSCL),…
Plus Therapeutics Reports Stockholders Equityin Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
August 15, 2025 07:30 ET | Source: Plus Therapeutics Inc. HOUSTON, Aug.…
